/
Oncology
Hematologic Malignancies
58
Pipeline Programs↗
62
Active Trials↗
76
Companies Involved↗
Hematologic Malignancies is a moderately active landscape with 58 programs across 76 companies. The most active players are CRISPR Therapeutics, IDP Discovery Pharma S.L., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 130
Phase 225
Phase 31
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
41 of 52 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 100% of 58 pipeline programs.
Analysis
Trial Status
266
clinical trials
Completed121 · 45%
Terminated49 · 18%
Recruiting43 · 16%
Withdrawn18 · 7%
Unknown status15 · 6%
Active, not recruiting9 · 3%
Other11 · 4%
Clinical Trials
Trial Activity
266 trials
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Recruiting·CCenter for International Blood and Marrow Transplant Research·N/A·NCT01351545·99,999 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)